ÂÜÀòÂÒÂ×

Dr. Wilfried Hauke is a physician by training specialized in pharmaceutical medicine. With more than 30 years of working in various fields of the pharmaceutical industry, he gained outstanding experience in designing and leading clinical research studies, drug development, and regulatory strategies.

Wilfried exhibits a wide range of competencies in management and consulting starting his career at Hoechst AG, Frankfurt, and Roussel UCLAF, Paris where he was involved in the clinical development of antibiotics and cardiovascular drugs. More recently Wilfried took over responsibility as CMO for Trophos, Marseille, and was key in medical matters of their assets, which were successfully acquired by Roche in 2015.

As CMO and board member of a stock-listed company, Wilfried adapted the lead compound development strategy and initiated change management processes. Throughout his career, he successfully set focus in risk-benefit-analysis and completed due diligence projects supporting seller and purchaser perspectives.

He serves as Qualified Person for Pharmacovigilance for UK-based pharma companies and supports as Medical Advisor orphan drug developments. Wilfried built up a strong network of research specialists as well as high-ranking industrial partners and investors. Wilfried joined Cardior as CMO in early 2018.